Advertisement
UK markets close in 8 hours 20 minutes
  • FTSE 100

    8,198.78
    0.00 (0.00%)
     
  • FTSE 250

    21,138.68
    0.00 (0.00%)
     
  • AIM

    783.24
    0.00 (0.00%)
     
  • GBP/EUR

    1.1869
    -0.0003 (-0.02%)
     
  • GBP/USD

    1.2925
    -0.0008 (-0.06%)
     
  • Bitcoin GBP

    51,485.48
    -603.15 (-1.16%)
     
  • CMC Crypto 200

    1,370.38
    -14.88 (-1.07%)
     
  • S&P 500

    5,564.41
    +59.41 (+1.08%)
     
  • DOW

    40,415.44
    +127.91 (+0.32%)
     
  • CRUDE OIL

    79.95
    +0.17 (+0.21%)
     
  • GOLD FUTURES

    2,391.60
    -3.10 (-0.13%)
     
  • NIKKEI 225

    39,594.39
    -4.61 (-0.01%)
     
  • HANG SENG

    17,480.93
    -154.95 (-0.88%)
     
  • DAX

    18,407.07
    +235.14 (+1.29%)
     
  • CAC 40

    7,622.02
    0.00 (0.00%)
     

Celldex Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line

Celldex Therapeutics (NASDAQ:CLDX) Full Year 2022 Results

Key Financial Results

  • Net loss: US$112.3m (loss widened by 59% from FY 2021).

  • US$2.40 loss per share (further deteriorated from US$1.65 loss in FY 2021).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Celldex Therapeutics Revenues Beat Expectations

Revenue exceeded analyst estimates by 141%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are up 12% from a week ago.

Risk Analysis

Be aware that Celldex Therapeutics is showing 3 warning signs in our investment analysis and 1 of those is potentially serious...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here